Viva Biotech Holdings · HKEX:1873
Viva Biotech — FY2025 Earnings Presentation
32 slides from Viva Biotech's earnings presentation, Mar 31, 2026
Slide 1: Viva Biotech 2025 Annual Results Conference
Viva Biotech 2025 Annual Results Conference Date: March 31, 2026 (Tuesday) Time: 21:00 PM (CST) 09:00 AM (EST) Language: English
Slide 2: Forward-Looking Statements
Forward-Looking Statements Certain information set forth in this presentation contains “forward-looking statements” which are not historical facts, but instead are predictions about future events based on our beliefs as well as assumptions made by and information currently available to our managemen
Slide 3: Content
CONTENT 01 Business Highlights 02 Financial Performance 03 Future Strategies Q&A Session
Slide 4: Part 1: Business Highlights
Viva PART 1: Business Highlights
Slide 5: World Leading One-stop Innovative Original Drug R&D and Production Platform
World Leading One-stop Innovative Original Drug R&D and Production Platform CDMO Research and EFS Investment and CRO Business Production Business Incubation Business Focus on FIC's Discover business, take Provide innovative drug partners with small Focus on discovering and investing SBDD as the core
Slide 6: Equity Structure of Viva Biotech
Equity Structure of Viva Biotech Viva Biotech Holdings (1873.HK) 10.87% Strategic investors 26.34% 72.9% 100% 100% Small Molecule Incubator CRO CDMO 100% 100% 100% Onshore Offshore Shanghai Jiaxing Suzhou Chengdu Overseas Shanghai Ningbo Taizhou Equity Incubators Equity Holding Holding Platform Plat
Slide 7: Integrated Platform for Comprehensive Original Drug R&D and Manufacturing Services
Integrated Platform for Comprehensive Original Drug R&D and Manufacturing Services One-stop R&D Service Platform for Innovative Novel Drugs Affinity-Based Drug Screening Peptides Protein and Mass Spectrometry (ASMS, INTACT-MS) SPR Drug Oligo Nucleotides Crystal Soaking Metabolism （PPO） Protein Scien
Slide 8: Business Highlights Overview
Overview Business Highlights RMB Million ⚫ Revenue in FY2025 reached RMB 1729.4 million, gross profit reached RMB 2500 40.0% 655.6 million 2155.6 37.9% 38.0% ⚫ Gross profit margin 37.9%, +3.3pp YOY 1986.7 34.6% 2000 36.0% 34.3% ⚫ Adjusted net profit reached RMB 335.3 million, +6.6% YOY 1729.4 34.0%
Slide 9: CRO Business: Sustained Recovery of Revenue Growth
Business Highlights CRO Business：Sustained Recovery of Revenue Growth, Sharp Increase in Domestic Revenue ⚫ Revenue: RMB 848.6 million, +4.7% YOY RMB Million ⚫ Adjusted gross profit: RMB 383.1 million, +7.3% YOY CFS SFE ⚫ Adjusted gross profit margin:45.1%, +1.1pp YOY 1.4 ⚫ Top 10 Customer Revenue C
Slide 10: CRO Business: Operational Efficiency and Growing Number of Customers
CRO Business：Operational Efficiency Continues to Improve and the Number of Customers Grows Steadily CRO R&D Personnel Remain Stable and Served Top 50 Global Operational Efficiency Continues to Improve Pharmaceutical Companies 2025 1123 2024 1121 2023 1155 Based on Total Annual Revenue in FY2025 Numb
Slide 11: CRO Business: Increase in Targets and Protein Structures Delivered
CRO Business：Solid Operations with Continued Increase in the Number of Targets and Protein Structures Delivered Rapid Improvement in Radiation Source Continuous Increase in Delivered Targets Efficiency, Decline in Usage Duration Unit: hours and Protein Structures 2025 1673 2024 1867 ⚫ Independent Ta
Slide 12: AI Technology Driven Experiments Pave the Way for a New Era
AI Technology Driven Experiments Pave the Way for a New Era in Drug Development Target Safety and Efficacy Hit Identification Lead Optimization Identification Evaluation Virtual Screening and ADME/PK AI Structure Prediction Free Energy Perturbation Molecular Generation Property Prediction Viva Struc
Slide 13: AI-driven Drug Design – a New Pharmaceutical Logic
AI-driven Drug Design – a New Pharmaceutical Logic 16-25 weeks 6-12 weeks 6-24 months 12-36 months Screening Validation Hit-to-Lead Lead Optimization Target • Protein production • Resynthesis and testing • Compound activity optimization • Molecule design Selection • HTS screening • Orthogonal assay
Slide 14: AI-Driven Drug Discovery: Three Core Modules of the AIDD Platform
AI-Driven Drug Discovery—Three Core Functional Modules of the AIDD Platform • End-to-End Cyclic Peptide Platform • Biological Large Language Model(Bio-LLM) • All-Atom Complex Prediction • Generative Modality Optimization • PDC & Linker Co-Design/Generation • Active-learning Augmented Virtual • Antib
Slide 15: CDMO R&D and Production Services Business Highlights
Business Highlights CDMO R&D and Production Services RMB Million ⚫ Revenue of Langhua: RMB 880.8 million, adjusted gross profit of Langhua: RMB 286.6 561.7 million ⚫ Adjusted gross profit margin of Langhua: 32.5%, +3.2pp YOY ⚫ CDMO: Revenue RMB 561.7 million; adjusted gross profit margin 39.9%, +1.3
Slide 16: CDMO Business: New Commercialization Projects and Capacity Construction
CDMO Business: New Commercialization Projects Showed Promise and Capacity Construction Steadily Advance Revenue and Adjusted Gross Profit from CDMO RMB Million C 1 A1 561.7 B 1 224.1 2025 Revenue Adjusted Gross Profit ⚫ Revenue from CDMO: RMB 561.7 million; The decrease in revenue was primarily attr
Slide 17: Optimized CMC Operations, Enabling Continuously Improved Profitability
Optimized CMC Operations, Enabling Continuously Improved Profitability Constant Increase in the Number of CMC Projects The Overall CMC R&D Staff Remain Stable Projects Persons 2025 295 2025 96 2024 255 2024 113 2023 183 2023 113 • During the Reporting Period, the Group adjusted and optimized the CMC
Slide 18: EFS Investment & Incubation Business Highlights
Business Highlights EFS Investment & Incubation Business RMB Million ⚫ As the end of the reporting period，the Group has invested a total of 93 1575.2 portfolio companies. 1409.0 ⚫ During the reporting period，several portfolio companies achieved partially 1290.3 1180.4 1207.5 exits，which successfully
Slide 19: VBI Investment Exits and Components Overview
VBI Investment Exits and Components Overview ⚫ As of FY2025，VBI has invested in a total of 93 portfolio companies. The Group has successfully realized 19 investment exits or partial exits, and the enterprises invested in the incubation covered multiple indications, multiple molecular models and mult
Slide 20: Continuous Expansion of Drug Pipeline, with Ongoing Financing Progress
Continuous Expansion of Drug Pipeline, with Ongoing Financing Progress 231 Pipeline Projects in Portfolio Companies • In December 2025, Sobi entered an acquisition agreement with Arthrosi for up to US$1.5 billion, primarily targeting Arthrosi's gout candidate AR882 *Calculated Based on the Cumulativ
Slide 21: Key Projects in VBI Investment Portfolio
Key Projects in VBI Investment Portfolio No. Name Country Mechanism Indication Pipeline Company Overview A clinical-stage biotechnology company developing therapeutics for gout and chronic kidney disease. Its proprietary drug candidate, AR882, has Small Gout and 1 Arthrosi USA Molecule Tophus Clinic
Slide 22: Part 2: Financial Performance
PART 2: Financial Performance
Slide 23: Financial Performance of the Group: Significant YOY Growth in Net Profit
Financial Performance of the Group: Significant YOY Growth in Net Profit Revenue of the Group RMB million Adjusted Gross Profit RMB million 1986.7 1729.4 701.5 669.7 2024 2025 2024 2025 Adjusted Non-IFRS Net Profit Experienced a YOY Increase Net Profit Experienced a Significant YOY Increase RMB mill
Slide 24: CRO Financial Statistics
CRO Financial Statistics: Positive Growth in Both Revenue and Gross Profit, Continuous Improvement in Workforce Efficiency CRO Revenue RMB million Adjusted Gross Profit RMB million YOY Increased 4.7% YOY Increased 7.3% 810.9 848.6 357.1 383.1 2024 2025 2024 2025 No. of CRO R&D personnel Persons Annu
Slide 25: CDMO Financial Statistics
CDMO Financial Statistics: Resulting From the Optimization and Adjustment of Business Structure, the Gross Profit Margin Has Continuously Increased Revenue and Adjusted Gross Profit of Langhua Gross Profit Margin of Langhua Has Continuously Increased RMB million 1175.7 880.8 32.5% 29.3% 344.5 286.6
Slide 26: Revenue Classifications of Principal Activities
Revenue Classifications of Principal Activities As at December 31, 2025 CDMO and commercialization Drug discovery services VBI Total service Types of goods or services RMB’000 RMB’000 RMB’000 RMB’000 Revenue from non-investees Full-time-equivalent (FTE) 623,857 - - 623,857 Fee-for-service (FFS) 196,
Slide 27: Items Measured at Fair Value with Changes Recognized in Profit or Loss
Items Measured at Fair Value with Changes in Fair Value Recognized in Profit or Loss The movements in the carrying value of unlisted investments at FVTPL for the reporting period are as follows ： RMB’000 January 1, 2024 995,281 Acquired 20,147 Recognized from SFE revenue 7.782 Loss on fair value cha
Slide 28: Appendix: Adjusted Non-IFRS Net Profit
APPENDIX: Adjusted Non-IFRS Net Profit 2025FY 2025H1 2024FY 2024H1 2023FY RMB’000 RMB’000 RMB’000 RMB’000 RMB’000 Net Profit / (Loss) 269,267 148,637 221,987 144,237 -99,790 Add: Fair Value Gain on Financial Liabilities at FVTPL - - -174,323 Add: interest expenses of the debt components of the - - 1
Slide 29: Part 3: Future Strategies
Viva PART 3: Future Strategies
Slide 30: Improve Capacity Building for Front-end Projects, Expand Whole Industry Chain Service
Improve Capacity Building for Front-end Projects, Continue to Expand the Whole Industry Chain Service Downstream To Establish an Open and Cooperative Platform and a Win-win Ecosystem for Global Biopharmaceutical Innovators Early-stage preclinical service ⚫ Raise technology barriers and expand servic
Slide 31: Q&A Session
Viva Q&A Session
Slide 32: Viva Biotech 2025 Annual Results Conference
Viva Biotech 2025 Annual Results Conference Date: March 31, 2026 (Tuesday) Time: 21:00 PM (CST) 09:00 AM (EST) Language: English